The payers' perspective on gene therapies

Nature Biotechnology

Volumn 33, Issue 9, 2015, Pages 902-904

  Touchot, Nicolas ^a   Flume, Mathias ^b  

^a GroupH   (United Kingdom)

^b Prescription Management ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; SOFOSBUVIR;

BUDGET; CONCURRENT SEXUAL PARTNERSHIP; DRUG COST; DRUG INDUSTRY; FOLLOW UP; GENE THERAPY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEART TRANSPLANTATION; HEPATITIS C; HUMAN; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LETTER; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REIMBURSEMENT; ECONOMICS;

GENETIC THERAPY; HUMANS;

EID: 84941109780     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3332     Document Type: Letter

References (6)

1. Brennan, T.A., Wilson, J.M. Nat. Biotechnol. 32, 874-876 (2014).
2. Ylä-Herttuala, S. Mol. Ther. 23, 217-218 (2015).
3. Hirschler, B. GSK readies "bubble boy" drug as big pharma bets on gene therapy. Reuters (27 April 2015). http://www.reuters.com/article/2015/04/27/health genetherapy-gsk-idUSL5N0XK2K120150427
4. Leleu, H. et al. J. Viral Hepat. 22, 376-383 (2015).
5. Hanson, S.G., Bentley, T.S. 2014 US organ and tissue transplant cost estimates and discussions (Milliman Research, 30 December 2014).
6. Arons, I. The Ophthalmologist 0515, 601 (2015).